13 certified Labor Condition Applications on file with the U.S. Department of Labor, FY2021–FY2025.
Since September 2025, DOL's Project Firewall opens H-1B investigations without waiting for a complaint. These checkpoints come from ReCode Therapeutics, Inc.'s own public LCA filings (FY2023–FY2025) — the same records an investigator pulls first.
Withdrawn or denied LCAs are normal in isolation; a high share suggests workers were moved between filings and the paper trail needs checking.
Level I is the entry-level prevailing-wage tier and the band DOL's Project Firewall reviews first for misclassification (senior duties filed at an entry-level wage). The national share is 17%.
Median offered wage is 7% above the DOL prevailing wage across 9 recent certified LCAs. Paying at the floor is lawful, but it invites the question of whether the wage level itself is right.
Each worksite needs its own 10-business-day LCA notice and a PAF record of that posting; a move to a new area of intended employment needs a new LCA before the worker starts there.
Public DOL disclosure data can lag actual filings by a quarter. Descriptive only — not legal advice.
Yes — ReCode Therapeutics, Inc. sponsors H-1B workers, with 13 certified LCAs on file (FY2021–FY2025), including 1 in FY2025. The median certified salary is $115,000 (P25 $85,890, P75 $140,000). With a 44% transfer share, this employer actively accepts H-1B transfers. 100% of its certified filings meet or exceed the prevailing wage.
ReCode Therapeutics, Inc. H-1B sponsorship at a glance, from public U.S. DOL LCA disclosure data (FY2021–FY2025).
Certified LCAs are a prerequisite to H-1B petitions, not visa approvals; one LCA can cover multiple workers. Descriptive only — not legal advice.
The shaded band is the middle half of certified salaries (P25–P75); the bar spans the lowest to highest certified salary.
Levels I–IV are DOL prevailing-wage experience tiers; 50% of filings are senior-level (III–IV).
| Fiscal year | Certified | Denied | Withdrawn | Total |
|---|---|---|---|---|
| FY2021 | 2 | 0 | 0 | 2 |
| FY2022 | 2 | 0 | 0 | 2 |
| FY2023 | 6 | 0 | 0 | 6 |
| FY2024 | 2 | 0 | 1 | 3 |
| FY2025 | 1 | 0 | 2 | 3 |
Case dispositions from the U.S. DOL OFLC disclosure files. Withdrawn are LCAs that were certified and later withdrawn by the employer; they still count toward Total.
| Job title | Salary | Level | Location | Filed | Status |
|---|---|---|---|---|---|
Scientist I, In Vitro Pharmacology I-200-25104-862751 | $112,258/yr | II | Menlo Park, CA | Apr 14, 2025 | Certified |
Senior Director, Formulations and Process Development I-200-24156-070761 | $148,408/yr | IV | Menlo Park, CA | Jun 04, 2024 | Certified |
Research Associate II, Bioanalytical I-200-24124-957228 | $88,000/yr | IV | Menlo Park, CA | May 03, 2024 | Certified |
Scientist II I-200-23216-240578 | $130,000/yr | III | Menlo Park, CA | Aug 04, 2023 | Certified |
Research Associate II I-200-23192-181805 | $90,000/yr | IV | Menlo Park, CA | Jul 11, 2023 | Certified |
Research Associate, Aerosol - Lipid Nano Particle I-200-23123-989079 | $79,560/yr | I | Menlo Park, CA | May 03, 2023 | Certified |
Senior Manager, IT Infrastructure and Security I-200-23111-955630 | $185,000/yr | II | Menlo Park, CA | Apr 21, 2023 | Certified |
Scientist II I-200-23107-940552 | $140,000/yr | IV | Menlo Park, CA | Apr 17, 2023 | Certified |
Senior Research Associate I, Gene Editing I-200-23061-815892 | $115,000/yr | III | Menlo Park, CA | Mar 01, 2023 | Certified |
Senior Research Associate I I-200-22144-207709 | $76,000/yr | II | Dallas, TX | May 24, 2022 | Certified |
Aerosol Scientist II I-200-22144-207721 | $120,000/yr | II | Menlo Park, CA | May 24, 2022 | Certified |
Director of Formulation Development I-200-21242-554201 | $215,000/yr | II | Menlo Park, CA | Aug 30, 2021 | Certified |
Research Associate II I-200-21242-554183 | $58,000/yr | II | Dallas, TX | Aug 30, 2021 | Certified |
One row per LCA case (its latest version), from U.S. DOL OFLC disclosure data. Salaries are the offered wage, converted to a yearly figure. Certified LCAs are not visa approvals.
Worker positions by LCA filing purpose, summed across FY2021–FY2025 disclosure records.
Most active filing months: May and Apr — useful for timing transfer conversations.
Attestations from the employer's own LCA filings (Form ETA-9035), as disclosed by the U.S. DOL.
2 states · 2 cities
The same DOL data on this page is what every H-1B sponsor must track for each worker. ElevateStaffing.ai automates it end-to-end:
Get the private PAF / LCA gap check for your own filings — free, one business day — then let ElevateStaffing.ai keep every LCA, PAF, I-9 and I-983 deadline audit-ready.
Get my private gap check →